A study on the expression of Her2/neu in malignant epithelial ovarian tumors
Background: Ovarian cancer poses a considerable challenge in surgical treatment, often requiring careful and complex approaches. A review of the literature highlights a wide range of Her2/neu overexpression or amplifications in ovarian tumors, with reported rates between 8% and 66%. This variability...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
| Series: | MGM Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.4103/mgmj.mgmj_235_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841525486768881664 |
|---|---|
| author | Amit Kumar Bhardwaj Vanita Bhaskar Rashmi Nayak Anubhav Chandrakar Vikas Bombeshwar Vikas Kailashiya |
| author_facet | Amit Kumar Bhardwaj Vanita Bhaskar Rashmi Nayak Anubhav Chandrakar Vikas Bombeshwar Vikas Kailashiya |
| author_sort | Amit Kumar Bhardwaj |
| collection | DOAJ |
| description | Background: Ovarian cancer poses a considerable challenge in surgical treatment, often requiring careful and complex approaches. A review of the literature highlights a wide range of Her2/neu overexpression or amplifications in ovarian tumors, with reported rates between 8% and 66%. This variability may be associated with chemotherapy resistance and poor treatment outcomes, thereby playing a significant role in prognosis. Objective: We aimed to study the expression of Her2/neu in malignant epithelial ovarian tumors using immunohistochemistry. Materials and Methods: This descriptive, observational (cross-sectional) study was conducted in the Department of Pathology at Pt. Jawaharlal Nehru Memorial Medical College, Raipur, Chhattisgarh, India, from August 2022 to December 2023, over 18 months. Seventy cases of malignant epithelial ovarian tumors were included. The immunohistochemical analysis assessed the expression pattern of the Her2/neu protein in these tumors. Results: Among the 70 cases, the majority were serous carcinomas (n = 47, 67.2%), with low-grade serous carcinoma (n = 24, 34.3%) being slightly more common than high-grade serous carcinoma (n = 23, 32.9%). Fourteen cases (20%) were mucinous cystadenocarcinomas, and nine (12.9%) were endometrioid carcinomas. The mean age of the study population was 52.58 ± 2.80 years, with the highest proportion of cases (n = 25, 35.7%) observed in the perimenopausal age group (40–50 years). Her2/neu positivity was observed in 15 cases (21.4%) of the 70 malignant epithelial ovarian tumors. Conclusion: Her2/neu protein overexpression was found in 21.4% (n = 15) of cases. No statistically significant association was observed between Her2/neu overexpression and the histological subtype or the age of the patients. |
| format | Article |
| id | doaj-art-ba2b0f1858bb4774b6865fbdc9c2aaaf |
| institution | Kabale University |
| issn | 2347-7946 2347-7962 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | MGM Journal of Medical Sciences |
| spelling | doaj-art-ba2b0f1858bb4774b6865fbdc9c2aaaf2025-01-17T10:55:34ZengWolters Kluwer Medknow PublicationsMGM Journal of Medical Sciences2347-79462347-79622024-12-0111460360910.4103/mgmj.mgmj_235_24A study on the expression of Her2/neu in malignant epithelial ovarian tumorsAmit Kumar BhardwajVanita BhaskarRashmi NayakAnubhav ChandrakarVikas BombeshwarVikas KailashiyaBackground: Ovarian cancer poses a considerable challenge in surgical treatment, often requiring careful and complex approaches. A review of the literature highlights a wide range of Her2/neu overexpression or amplifications in ovarian tumors, with reported rates between 8% and 66%. This variability may be associated with chemotherapy resistance and poor treatment outcomes, thereby playing a significant role in prognosis. Objective: We aimed to study the expression of Her2/neu in malignant epithelial ovarian tumors using immunohistochemistry. Materials and Methods: This descriptive, observational (cross-sectional) study was conducted in the Department of Pathology at Pt. Jawaharlal Nehru Memorial Medical College, Raipur, Chhattisgarh, India, from August 2022 to December 2023, over 18 months. Seventy cases of malignant epithelial ovarian tumors were included. The immunohistochemical analysis assessed the expression pattern of the Her2/neu protein in these tumors. Results: Among the 70 cases, the majority were serous carcinomas (n = 47, 67.2%), with low-grade serous carcinoma (n = 24, 34.3%) being slightly more common than high-grade serous carcinoma (n = 23, 32.9%). Fourteen cases (20%) were mucinous cystadenocarcinomas, and nine (12.9%) were endometrioid carcinomas. The mean age of the study population was 52.58 ± 2.80 years, with the highest proportion of cases (n = 25, 35.7%) observed in the perimenopausal age group (40–50 years). Her2/neu positivity was observed in 15 cases (21.4%) of the 70 malignant epithelial ovarian tumors. Conclusion: Her2/neu protein overexpression was found in 21.4% (n = 15) of cases. No statistically significant association was observed between Her2/neu overexpression and the histological subtype or the age of the patients.https://doi.org/10.4103/mgmj.mgmj_235_24high-grade serouslow-grade serousmalignant epithelial tumormucinousovary |
| spellingShingle | Amit Kumar Bhardwaj Vanita Bhaskar Rashmi Nayak Anubhav Chandrakar Vikas Bombeshwar Vikas Kailashiya A study on the expression of Her2/neu in malignant epithelial ovarian tumors MGM Journal of Medical Sciences high-grade serous low-grade serous malignant epithelial tumor mucinous ovary |
| title | A study on the expression of Her2/neu in malignant epithelial ovarian tumors |
| title_full | A study on the expression of Her2/neu in malignant epithelial ovarian tumors |
| title_fullStr | A study on the expression of Her2/neu in malignant epithelial ovarian tumors |
| title_full_unstemmed | A study on the expression of Her2/neu in malignant epithelial ovarian tumors |
| title_short | A study on the expression of Her2/neu in malignant epithelial ovarian tumors |
| title_sort | study on the expression of her2 neu in malignant epithelial ovarian tumors |
| topic | high-grade serous low-grade serous malignant epithelial tumor mucinous ovary |
| url | https://doi.org/10.4103/mgmj.mgmj_235_24 |
| work_keys_str_mv | AT amitkumarbhardwaj astudyontheexpressionofher2neuinmalignantepithelialovariantumors AT vanitabhaskar astudyontheexpressionofher2neuinmalignantepithelialovariantumors AT rashminayak astudyontheexpressionofher2neuinmalignantepithelialovariantumors AT anubhavchandrakar astudyontheexpressionofher2neuinmalignantepithelialovariantumors AT vikasbombeshwar astudyontheexpressionofher2neuinmalignantepithelialovariantumors AT vikaskailashiya astudyontheexpressionofher2neuinmalignantepithelialovariantumors AT amitkumarbhardwaj studyontheexpressionofher2neuinmalignantepithelialovariantumors AT vanitabhaskar studyontheexpressionofher2neuinmalignantepithelialovariantumors AT rashminayak studyontheexpressionofher2neuinmalignantepithelialovariantumors AT anubhavchandrakar studyontheexpressionofher2neuinmalignantepithelialovariantumors AT vikasbombeshwar studyontheexpressionofher2neuinmalignantepithelialovariantumors AT vikaskailashiya studyontheexpressionofher2neuinmalignantepithelialovariantumors |